ABVX PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

ABVX ▲ +2.59% at T+5d

NEUTRAL call ✓ call won +2.59% · α vs SPY +1.51% · entry $126.41 → $129.69

Next anchor: T+20d in 13d

Last close $101.53 (close Jun 8) · -19.68% from $126.41 entry

Entry anchored
May 22, 03:59 PM ET
via Databento tick

T+1d

+2.94%

call +2.94% · α +2.99%

$130.13

settled 15d ago

T+5d

+2.59%

call +2.59% · α +1.51%

$129.69

settled 9d ago

T+20d

—

call — · α —

—

in 13d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Abivax reported Q1 2026 net loss of €48.5M (vs €52.4M loss in Q1 2025) with operating loss of €56.2M. The press release highlights durable Phase 2 clinical remission data (68% at week 144 on 25mg de-escalation) and €491.6M cash runway into Q4 2027. The company is pre-revenue with a biotech pipeline catalyst — the ABTECT Phase 3 UC maintenance trial top-line results due late Q2 2026 is the near-term binary event.

Actionable Insight

The near-term binary catalyst is the ABTECT Phase 3 UC maintenance top-line data, expected within ~4-6 weeks. Positive data would de-risk NDA submission pathway and likely drive a re-rating. Failure would significantly impair the asset's value. The cash position through Q4 2027 is sufficient to cover ongoing operations and clinical programs through key milestones, including the Phase 3 readout.

Key Facts

Operational loss of €56.2M in Q1 2026 vs €47.2M in Q1 2025
Net loss of €48.5M vs €52.4M year-over-year (improved by financial gain)
Cash, cash equivalents and short-term investments of €491.6M as of March 31, 2026
Cash runway projected into Q4 2027
Phase 3 ABTECT-UC maintenance trial top-line results expected late Q2 2026
130 patients de-escalated to 25mg obefazimod; 68% in clinical remission at week 144 (ITT)
NDA submission for obefazimod in UC planned for Q4 2026 (subject to positive data)
Phase 2b CD induction trial top-line results expected Q4 2026
R&D spend increased 26% YoY to €49.5M, driven by new indications and CD program
Equity offering of $45M (€38.5M) ADS completed May 5, 2026

Financial Impact

Pre-revenue clinical biotech — no revenue to evaluate. Q1 2026 operating loss €56.2M vs €47.2M in Q1 2025; net loss improved by financial gain (€8.0M vs -€5.2M). Cash burn from operations was €50.5M in Q1 2026 vs €33.3M in Q1 2025.

cash runwayoperating lossR&D spend

Risk Factors

Phase 3 ABTECT-UC maintenance trial may fail to meet endpoints — binary risk for the stock near-term
Pre-revenue stage with high cash burn rate (€50.5M operating cash outflow in Q1 2026)
Dilution risk from ADS offering completed May 5, 2026 ($45M)
Regulatory and commercial execution risk for obefazimod in UC and CD indications

Market Snapshot

Exchange

OTC

Sector

Pharmaceutical Preparations

Analyst Consensus

86% bullish (14 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3300344

2 reports for ABVX

T+1T+5T+20T+60

Filters

Reports for ABVX — sortable, filterable
	Type				Now
May 22, 2026 18d ago	Press Release NEUTRAL ★ 5/10	$126.41 $129.69	▲ +2.59%	▲ +1.51%	$101.53 (−19.68%)
Mar 23, 2026 11w ago	Press Release MIXED ★ 6/10	$110.17 $111.35	▲ +1.07%	▲ +1.49%	$101.53 (−7.84%)

US Market Status

Market Closed — Opens in 6h 7m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access